secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001437749-25-005338
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences licenses Yale simufilam patent for TSC-related seizures; up to $4.5M milestones
--------------------------------------------------------------------------------

- Exclusive worldwide license to issued US method of treatment patent (US 12,186,307) for simufilam in TSC-related epilepsy and other indications.
- Financial terms: nominal upfront, up to $4.5M in clinical/regulatory/commercial milestones, tiered low-to-mid single-digit % royalties on net sales.
- Based on Yale research (Bordey et al., Science Translational Medicine 2020) showing simufilam reduced seizure frequency in an animal model.
- Cassava to prioritize initial development on TSC-related seizures and plans preclinical studies with the TSC Alliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/0001437749-25-005338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/sava20250224_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-005338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer